A5032473973- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Immunotherapy and Immune Responses
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- RNA modifications and cancer
- Cancer Genomics and Diagnostics
- Cancer Research and Treatments
- Pleural and Pulmonary Diseases
- Brain Metastases and Treatment
- Cytokine Signaling Pathways and Interactions
- Monoclonal and Polyclonal Antibodies Research
- Cancer therapeutics and mechanisms
- Radiomics and Machine Learning in Medical Imaging
- Cancer-related molecular mechanisms research
- Neuroendocrine Tumor Research Advances
- vaccines and immunoinformatics approaches
- Cancer, Lipids, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Chronic Lymphocytic Leukemia Research
- Synthesis and biological activity
- Cancer Cells and Metastasis
Shanghai Pulmonary Hospital
2016-2025
Tongji University
2016-2025
Shanghai East Hospital
2024
Wuxi Fourth People's Hospital
2017
Tongji Hospital
2016
Cancer Institute (WIA)
2015
Medical University of South Carolina
2014
Immune checkpoint inhibitors targeting the programmed cell death receptor/ligand 1 (PD‐1/PD‐L1) pathway have profoundly improved clinical management of non‐small‐cell lung cancer (NSCLC). Nevertheless, superiority single‐agent PD‐1/PD‐L1 in pretreated EGFR mutant patients has turned out to be moderate. One proposed mechanism for poor response immune is an immunosuppressive tumor microenvironment. Therefore, we utilized two autochthonous ‐driven models investigate dynamic microenvironmental...
Abstract Central and peripheral extensive‐stage small‐cell lung cancer (ES‐SCLC) are reported to be two distinct tumor entities, but their responses the front‐line therapies underlying biological mechanisms remain elusive. In this study, we first compared outcomes of central ES‐SCLC receiving chemotherapy or chemo‐immunotherapy with a cohort 265 patients. Then performed single‐cell RNA sequencing (scRNA‐seq) on nine treatment‐naïve samples investigate potential response differences. Under...
Growing evidence suggests that acquired resistance to targeted therapy in non-small cell lung cancer patients is linked the mutual domestication between tumour and its surrounding microenvironment.Our study aims explore remodelling of microenvironment after osimertinib treatment resistance.We took RNA-seq-based immune infiltration analysis using TIMER 2.0. We carried out flow cytometry assay real-time interaction cells cells. In addition, we analysed exosomes via miRNA-seq label-free...
Abstract To investigate the prognostic value of PD ‐L1 expression combined with CD 8 + TIL s density in patients resected NSCLC and correlations clinicopathological features. We retrospectively enrolled 178 from 2011 to 2015. All surgical primary 58 matched metastatic lymph node specimens were tested for ‐L1, s, oncogenic alterations. was detected 71 (39.9%) high 74 (41.6%) cases. Smoking, Sq CC , EGFR − associated both s. Patients had longer OS ( P = 0.012). significantly alterations...
Osimertinib has become standard care for epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) patients whereas drug resistance remains inevitable. Now we recognize that the interactions between tumor and microenvironment (TME) also account resistance. Therefore, provide a new sight into post-osimertinib management, focusing on alteration of TME.
Multisensory integration (MSI) is a crucial process by which organisms combine information from multiple senses to enhance their perception and adapt the environment. This review focuses on MSI in Drosophila, an ideal model organism due its well-characterized neural circuitry genetic tractability. We first describe five main sensory modalities (vision, olfaction, gustation, mechanosensation, thermosensation) how they contribute Drosophila’s behavior. Then, we discuss basic models of MSI,...
Despite immune checkpoint inhibitors (ICI) being widely used to treat patients with advanced non-small cell lung cancer (NSCLC), few studies examine the role of ICI in proto-oncogene B-Raf, serine/threonine kinase (BRAF) mutations.A retrospective study was conducted for BRAF-mutant NSCLC who received treatment at Shanghai Pulmonary Hospital between 2014 and 2022. Primary end point progression-free survival (PFS). Secondary best response (RECIST, version 1.1).The involved a total 34 54...
Metastases to the central nervous system (CNS) are devastating neurological complications. Circulating cell-free tumor DNA (ctDNA) from cerebrospinal fluid (CSF) better represents genomic alterations in CNS tumors compared plasma (PLA). However, clinical value of as a liquid biopsy medium non-small cell lung cancer patients with leptomeningeal metastases (NSCLC-LM), regardless extracranial evolution, remains unclear.14/48 NSCLC-BM and 34/48 NSCLC-LM were enrolled this study. The mutation...
Abstract Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) provide a better prognosis in EGFR -mutant non-small cell lung cancer (NSCLC). Nevertheless, the outcome of leptomeningeal metastasis (LM) remains poor. In addition, due to limited access intracranial tumour tissue, gene alterations associated with from adenocarcinoma (LM-LUAD) are unclear. Methods Forty-five patients LM-LUAD May 2019 June 2021 Guangdong Sanjiu Brain Hospital were enrolled this study....
To investigate the effect of percutaneous electrical stimulation on chemotherapy-induced bone marrow suppression in patients with lung cancer.From December 2014 to August 2015, one hundred ninety-one non-small cell cancer chemotherapy naive were randomly divided into control group, medication and transcutaneous acupoint (TEAS) group. Patients group received routine nursing care, was treated by oral administration prophylactic agents, TEAS acupoints including Dazhui (DU14), Geshu (BL17),...
Background Leptomeningeal metastases (LM) have become increasingly common in non-small cell lung cancer (NSCLC) patients who harbor epidermal growth factor receptor ( EGFR ) mutation treated with -TKI and are correlated inferior prognosis. Evidence prior research demonstrated that amplification was more likely presented advanced clinical stages associated worse survival. However, whether is a prognostic marker NSCLC–LM still inconclusive. Methods This study enrolled diagnosed from June 2019...
Immunotherapy using dendritic cell (DC) vaccine has the potential to overcome bottleneck of cancer therapy.We engineered Lewis lung cells (LLCs) and bone marrow-derived DCs express tumor-associated antigen (TAA) ovalbumin (OVA) via lentiviral vector plasmid encoding OVA gene. We then tested antitumor effect modified both in vitro vivo.The results demonstrated that could dramatically enhance T-cell proliferation (P<.01) killing LLCs than control groups (P<.05). Moreover, reduce tumor size...
The therapeutic cancer vaccine recombinant Epidermal Growth Factor (EGF)-CRM197 is a novel combined conjugate EGF with CRM197 as carrier protein. Immunization the EGF-CRM197 can induce high levels of neutralizing anti-EGF antibodies that inhibit EGF/EGFR signaling and thereby suppress growth tumors rely on this pathway. Herein, we characterize humoral immune responses elicited by in patients advanced solid phase I clinical trial assess safety, tolerability, immunogenicity (CTR20190473).A...